Skip to content
Stork.AIstork.ai
AI Tool

Isomorphic Labs Review

Isomorphic Labs is an AI-driven drug discovery company that uses AI to design new medicines by predicting and generating protein shapes and sequences.

shipped Apr 2, 2026aifreemium
ai
Isomorphic Labs - AI tool for isomorphic labs. Professional illustration showing core functionality and features.

Why it matters

1Isomorphic Labs was spun out of DeepMind in 2021 as an Alphabet company.
2The company secured $600 million in Series B funding in March 2025, valuing it at $3.5 billion.
3In May 2024, Isomorphic Labs jointly released AlphaFold 3 with Google DeepMind, enabling modeling of all life's molecules.
4Strategic collaborations were announced with Eli Lilly and Company and Novartis AG in January 2024, and Johnson & Johnson in January 2026.

Stork’s verdict on Isomorphic Labs

Isomorphic Labs offers an AlphaFold 3-backed drug design engine for accelerated discovery, yet its specialized focus suits only enterprise-level R&D.

Specs

API Available

Yes, public API

overview

What is Isomorphic Labs?

Isomorphic Labs is an AI-driven drug discovery tool developed by Alphabet that enables pharmaceutical companies and researchers to design novel medicines by predicting and generating protein shapes and sequences. It leverages advanced AI to accelerate the entire drug discovery process, aiming to solve all diseases. Spun out of DeepMind in 2021, Isomorphic Labs employs an AI-first approach to reimagine drug discovery, utilizing a unified AI drug design engine. This engine is built on models capable of operating across multiple therapeutic areas and drug modalities, conducting extensive experimental work "in silico" to explore new chemical spaces and tackle previously intractable targets. The company's technology builds upon the foundational AlphaFold breakthroughs, extending capabilities to predict 3D protein structures and their interactions with other molecules with high accuracy.

features

Key Features of Isomorphic Labs

Isomorphic Labs provides a suite of AI-driven capabilities designed to accelerate and enhance the drug discovery process, moving beyond traditional experimental methods.

  • Uses AI to design new medicines by predicting and generating protein shapes and sequences.
  • Models complex biological phenomena to design novel molecules with specific properties.
  • Predicts how drugs will perform and interact with biological systems with high accuracy.
  • Accelerates the drug discovery pipeline by significantly reducing reliance on wet lab experiments.
  • Identifies new binding pockets on target proteins using only amino acid sequences.
  • Develops new drug candidates across multiple therapeutic areas and modalities, including oncology and immunology.
  • Leverages AlphaFold 3 technology for unprecedented accuracy in modeling structures and interactions of all life's molecules.
  • Features a Drug Design Engine that reportedly doubled AlphaFold 3's performance on a protein-ligand structure prediction generalization benchmark (February 2026).

use cases

Who Should Use Isomorphic Labs?

Isomorphic Labs is primarily designed for entities and professionals engaged in advanced pharmaceutical research and development, seeking to leverage AI for novel drug discovery.

  • Pharmaceutical companies: For accelerating drug discovery pipelines, exploring new chemical spaces, and designing novel molecules for various therapeutic areas.
  • Biomedical companies: To model complex biological phenomena, predict drug performance, and identify new therapeutic targets more efficiently.
  • Drug discovery experts and computational chemists: For identifying new binding pockets on target proteins and developing new drug candidates with enhanced precision.
  • Medicinal chemists: To design new drug candidates with specific properties, moving beyond traditional screening methods.
  • Researchers in biology, chemistry, and medicine: For leveraging advanced AI in understanding molecular interactions and accelerating fundamental research into disease mechanisms.

pricing

Isomorphic Labs Pricing & Plans

Isomorphic Labs operates on a freemium model. Specific details regarding pricing tiers, feature limitations for the free tier, or enterprise-level costs are not publicly disclosed. The company primarily engages in strategic collaborations with pharmaceutical partners, such as Eli Lilly and Company, Novartis AG, and Johnson & Johnson, which likely involve custom agreements, milestone payments, and royalties rather than standardized subscription plans.

Similar Tools

Isomorphic Labs vs Competitors

Isomorphic Labs operates within a competitive landscape of AI-driven drug discovery companies, each offering distinct approaches to leveraging artificial intelligence for therapeutic development.

1
Generate BiomedicinesOn StorkCompare

Generate Biomedicines uses a generative AI platform to design novel protein therapeutics from scratch, focusing on a diverse range of therapeutic modalities.

Similar to Isomorphic Labs, Generate Biomedicines focuses on de novo protein design for drug discovery. Their platform emphasizes generating a broader spectrum of therapeutic modalities, whereas Isomorphic Labs explicitly mentions predicting and generating protein shapes and sequences. Pricing is likely enterprise-based, contrasting with Isomorphic Labs' stated freemium model.

2
Xaira Therapeutics↗

Xaira Therapeutics integrates cutting-edge AI research, including technologies like RFdiffusion, with therapeutic development to design novel proteins and antibodies for complex biological challenges.

Like Isomorphic Labs, Xaira Therapeutics leverages advanced AI for protein and antibody design in drug discovery. Xaira appears to have a strong focus on integrating academic AI breakthroughs directly into therapeutic development, potentially offering a broader range of AI models for novel protein and antibody generation.

3
Latent Labs↗

Latent Labs is building generative AI models for de novo protein design, with a focus on creating entirely new therapeutic molecules like antibodies and enzymes to make biology more programmable.

Latent Labs directly competes with Isomorphic Labs in the de novo protein design space, aiming to generate entirely new therapeutic molecules. Their approach emphasizes a predominantly digital workflow with wet lab validation, aligning with Isomorphic's AI-first strategy for drug discovery.

4
DenovAI↗

DenovAI offers an AI-driven platform, AlphaDesign, capable of creating new, functional synthetic proteins entirely de novo without requiring training on evolutionary data or using known protein templates.

DenovAI is a direct competitor to Isomorphic Labs, both aiming to design novel proteins from scratch using AI. DenovAI highlights its ability to generate synthetic proteins without evolutionary templates, potentially offering a distinct approach to sequence and structure generation compared to Isomorphic Labs' methods.

5
ProteinQure↗

ProteinQure specializes in the AI-driven design of novel exotic peptides with broad therapeutic applications, leveraging its ProteinStudio™ computational platform for de novo peptide design and tissue-specific delivery.

ProteinQure, through its ProteinStudio™ platform, directly competes with Isomorphic Labs in AI-driven protein/peptide design for drug discovery. Its unique focus on exotic peptides and clinical-stage development for targeted delivery differentiates its therapeutic application, while Isomorphic Labs focuses more broadly on protein shapes and sequences.

Visit Isomorphic Labs↗

AI Reputation Report

Is Isomorphic Labs yours?

ChatGPT, Perplexity, Gemini, Claude & Grok answer buyer questions about Isomorphic Labs every day. See whether they name Isomorphic Labs — or send buyers to a rival.

See what AI saysfree preview

Featured in articles